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ABSTRACT 
 
Unsealed radionuclides have been in clinical therapeutic use for well over half a century. Following the early 
inappropriate clinical administrations of radium salts in the early 20th century, the first real clinical benefits became 
evident with the use of 
131I-sodium iodide for the treatment of hypothyroidism and differentiated thyroid carcinoma and 
32P-sodium phosphate for the treatment of polycythaemia vera. In recent years the use of bone seeking agents 
89Sr, 
153Sm and 
186Re for the palliation of bone pain have become widespread and considerable progress has been evident 
with the use of 
131I-MIBG and 
90Y-somatostatin receptor binding agents. Although the use of monoclonal antibody 
based therapeutic products has been slow to evolve, the start of the 21st century has witnessed the first licensed 
therapeutic  antibody  conjugates  based  on 
90Y  and 
131I  for  the  treatment  of  non-Hodgkin’s  lymphoma.  The  future 
clinical utility of this form of therapy will depend upon the development of radiopharmaceutical conjugates capable of 
selective binding to molecular targets. The availability of some therapeutic radionuclides such as 
188Re produced from 
the tungsten generator system which can produce activity as required over many months, may make this type of therapy 
more widely available in some remote and developing countries. 
Future products will involve cytotoxic radionuclides with appropriate potency, but with physical characteristics 
that  will  enable  the  administration  of  therapeutic  doses  with  the  minimal  need  for  patient  isolation.  Further 
developments  are  likely  to  involve  molecular  constructs  such  as  aptamers  arising  from  new  developments  in 
biotechnology.  
Patient trials are still underway and are now examining new methods of administration, dose fractionation and the 
clinical introduction of alpha emitting radiopharmaceutical conjugates. This review outlines the history, development 
and  future  potential  of  these  forms  of  therapy.  ©  2005  Biomedical  Imaging  and  Intervention  Journal.  All  rights 
reserved. 
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INTRODUCTION
        
 
Nuclear  medicine  therapy  is  based  on  the  use  of 
potent  radionuclides  normally  attached  to  a  ligand  or 
incorporated  into  a  conjugate  and  administered  to 
patients as unsealed radioactive sources. The underlying 
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principle is based on the selective molecular uptake of 
the agent in the lesion to be treated where it releases its 
cytotoxic  dose  of  radiation  with  minimal  uptake  in 
normal tissues. This form of treatment is often referred to 
as  targeted  radiotherapy,  however  the  term  “molecular 
targeted therapy” would be more appropriate. 
Initial interest in radionuclide therapy began during 
the early years of the 20th century with the inappropriate 
systemic  use  of  radium  salts  at  a  time  when  the  early 
radiologists considered radioactivity to be a “God given 
gift” with natural energising properties that could be used A.C. Perkins. Biomed Imaging Interv J 2005; 1(2):e9  2 
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for the benefit of mankind. 
226Radium was first isolated 
by the Curies in 1898 and was mainly used in the form of 
radium bromide, chloride, sulphate or carbonate. These 
early  radium  treatments  were  often  based  on  no  more 
than a solution for injection, drinking or bathing or as an 
ointment for topical application. In 1914 the title page of 
the  journal  “Radium”  contained  an  article  on  the 
influence of intravenous injection of soluble radium salts 
in high blood pressure [1]. Despite the lack of clinical 
evidence, radium treatments were claimed to have benefit 
in  the  treatment  of  a  range  of  conditions  including 
arthritis,  gout,  neuralgia,  lumbago,  menstrual 
irregularities, sexual disorders and obesity! 
Following the production of artificial radioactivity in 
the 1930s and 40s the first clinical treatments with 
32P 
and 
131I were undertaken. In particular the use of iodine 
for the treatment of thyrotoxicosis and thyroid cancer laid 
down the foundations for modern nuclear medicine. As 
the  science  of  nuclear  medicine  developed  and  the 
clinical  evidence  base  grew  there  has  been  a  growing 
interest in a range of radionuclides for targeted molecular 
radiotherapy.  However,  progress  has  been  slow  whilst 
radiochemists, physicists and clinicians have worked on 
the design and development of radionuclide conjugates 
for new and novel treatments. 
 
 
THERAPEUTIC RADIONUCLIDES 
 
Three  principle  factors  affect  the  suitability  of  a 
radionuclide for potential therapeutic use. These are the 
physical, chemical and biological properties. For therapy 
the biological effect is dependent upon the emission of 
potent radiation such as beta particles with high loss of 
energy  to  the  surrounding  medium  i.e.  high  Linear 
Energy  Transfer  (LET).  The  energy  of  the  emitted 
radiation is directly proportional to the path length of the 
dose deposition in tissue. This can be used to give an 
indication of the most appropriate size of lesion for any 
given  radionuclide.  Using  this  information  Wheldon  et 
al. [2] showed that 
131I with a mean beta path length of 
0.9 mm was most suited to treating 3 mm size tumours 
whereas  the  more  energetic  beta  emissions  from 
90Y 
would  be  more  effective  for  the  treatment  of  a  2  cm 
diameter tumour. One particular feature of this approach 
is  that  unlike  conventional  chemotherapy  the 
radiopharmaceutical  does  not  have  to  be  incorporated 
into every tumour cell to have a therapeutic effect. The 
path length of the emitted radiation is sufficient to allow 
effective therapy following uptake into a subpopulation 
of  cells.  This  is  generally  known  as  the  “Bystander 
Effect”.  A  list  of  some  of  the  main  therapeutic 
radionuclides is given in Table 1. 
For radionuclide imaging one of the main desirable 
requirements is for the radiopharmaceutical to contain a 
radionuclide  that  is  a  pure  gamma  emitter  or  at  least 
having  little  particle  emission  (e.g.  beta  or  alpha)  thus 
keeping unnecessary radiation burden to the patient to a 
minimum.  The  converse  is  true  for  therapy  since  the 
presence  of  high-energy  gamma  emission  from  a 
therapeutic  radiopharmaceutical  will  have  the  potential 
for  unnecessary  exposure  to  staff  and  relatives.  As  a 
result the patients require isolation after administration of 
the  therapeutic  agent  to  minimise  exposure  to  other 
individuals. This is the case with radioiodine treatment 
using 
131I, since the 365 keV gamma rays can lead to a 
high exposure to other patients, staff and members of the 
public. In practice this may restrict the more widespread 
introduction  of  some  therapeutic  radiopharmaceuticals 
based on 
131I. However, it is important to bear in mind 
that some gamma emission can be of value for imaging 
the uptake and biodistribution of the therapeutic agent. 
Indeed this can be extremely valuable for the assessment 
of individual patient dosimetry and in planning effective 
strategies  for  individual  patient  treatments.  This  will 
allow  treatment  protocols  based  on  tumour  dose 
prescriptions as performed in external beam radiotherapy 
[3]. 
In  addition  to  the  physical  characteristics  of  the 
therapeutic radionuclide, other obvious requirements are 
that  the  conjugation  of  the  targeting  molecule  to  the 
radionuclide should be reliable, practical and affordable. 
The final radiopharmaceutical conjugate must be suitable 
for patient administration, stable in vivo and effective at 
targeting the tumour receptor or binding site [4].  
 
 
Table 1 Physical characteristics of some therapeutic radionuclides 
 
Nuclide  Physical half-life  Emission  Mean path length 
       
125I  60.0d  auger  10 nm 
221At  7.2h  alpha  65 nm 
213Bi  46min  alpha  80 nm 
177L  6.7d  beta/gamma  0.7 mm 
67Cu  2.58d  beta/gamma  0.7 mm 
131I  8.04d  beta/gamma  0.9 mm 
153Sm  1.95d  beta/gamma  1.2 mm 
186Re  3.8d  beta/gamma  1.8 mm 
32P  14.3d  beta  2.9 mm 
188Re  17h  beta/gamma  3.5 mm 
114mIn  50d  beta/gamma  3.6 mm 
90Y  2.67d  beta  3.9 mm 
       
 
 
MECHANISMS OF UPTAKE 
 
A number of different mechanisms have been used 
to  achieve  selective  uptake  of  radiopharmaceuticals  in 
tissues.  These  are  metabolic  processes  such  as  with 
radioiodine,  radiophosphorus  and  meta-
iodobenzylguanidine;  the  use  of  specific  cell  surface 
receptors  for  example  using  radiolabelled  hormones, 
peptides and antibodies and by targeting the extracellular 
mechanisms using bone seeking agents and radiolabelled 
cells. 
In  oncology  a  feature  of  tumour  growth  is  the 
development  of  a  good  blood  supply  to  provide  the 
oxygen and nutrients necessary for cellular replication. 
The new tumour vessels are inherently leaky compared 
with  normal  blood  vessels.  This  is  due  to  wide  inter-
endothelial  junctions,  large  numbers  of  fenestrae  and 
transendothelial channels formed by vesicles as well as 
discontinuous or absent basement membranes [5,6]. As a 
result, capillary permeability of the endothelial barrier in 
newly vascularised tumours is significantly greater than 
that  of  normal  tissues  [7].  This  may  lead  to  increased A.C. Perkins. Biomed Imaging Interv J 2005; 1(2):e9  3 
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uptake of some agents since this is a function of both 
local  blood  flow  and  microvascular  permeability.  The 
amount  of  tissue  accumulation  of  a  conjugate  is 
proportional  to  plasma  clearance.  The  enhanced 
permeability  and  retention  (due  to  poor  lymphatic 
drainage  of  the  tumour)  may  lead  to  prolonged 
accumulation and retention of macromolecules in tumour 
interstitium [8]. 
There have been a number of successes in the field 
of targeting diagnostic tracers to tumours, since only a 
relatively small number of sites within a tumour need to 
take  up  the  tracer  for  effective  imaging.  However  the 
targeting  of  therapeutic  radiopharmaceuticals  for  the 
treatment  of  solid  tumours  is  difficult  and  as  such  a 
number  of  strategies  have  been  employed  such  as 
intralesional, intraarterial and intracavitary administration 
for example as in the treatment of glioma and superficial 
bladder cancer (see below). 
 
 
ESTABLISHED RADIOPHARMACEUTICAL THERAPIES 
 
Three forms of treatment are regarded as the longer 
running  and  more  established  forms  of  radionuclide 
therapy. These are 
131I-sodium iodide for the treatment of 
thyroid  carcinoma  and  thyrotoxicosis, 
32P-sodium 
phosphate  for  the  treatment  of  proliferative 
polycythaemia and 
90Y colloid, 
186Re-sulphide and 
169Er-
citrate  colloid  for  synovectomy  and  the  treatment  of 
malignant effusions.  
 
Thyroid 
Radioiodine treatment was developed in the 1950s 
and  was  one  of  the  very  first  of  the  modern  nuclear 
medicine  therapies. 
131I-sodium  iodide  is  available  in 
solution  form  or  as  hard  gelatin  capsule  both  for  oral 
administration. Once taken, it is absorbed rapidly (90% 
within the first hour) from the upper gastrointestinal tract. 
Within  the  thyroid  gland  iodine  is  taken  up  by 
differentiated  follicular  thyroid  cells  and  can  be 
considered  unique  in  nuclear  medicine.  Radioiodine  is 
used to treat both thyrotoxicosis (toxic diffuse goitre and 
toxic nodular goitre) and thyroid cancer. Approximately 
400  MBq  is  administered  for  the  treatment  of 
thyrotoxicosis.  Thyroid  cancer  is  a  relatively  common 
and  often  curable  malignant  neoplasm  that  usually 
presents with no symptoms other than a lump in the neck, 
which  may  be  solitary  or  multinodular.  In  the  United 
Kingdom, thyroid cancer represents approximately 1% of 
all  malignancy,  the  annual  incidence  being  reported  at 
0.9  per  100,000  men  and  2.3  per  100,000  women. 
Thyroid cancer accounts for nearly 2% of all new cancers 
diagnosed annually in the United States. The treatment 
options  have  evolved  considerably  over  recent  years 
however  the  use  of  radioiodine  remains  an  important 
consideration  in  the  practices  of  both  head  and  neck 
surgeons and endocrinologists [9]. Surgery (lobectomy or 
thyroidectomy) is the first choice of treatment followed 
by ablation with 
131I. Administered activities of 4 GBq 
and  8  GBq  are  used  to  treat  primary  and  metastatic 
disease  respectively.  Extensive  use  of  radioiodine  over 
the past 50 years has proven its efficacy, safety and cost 
effectiveness. It is remarkable since radioiodine treatment 
has the benefit of no sickness, no hair loss, no nausea, no 
diarrhoea and no pain. Radioiodine therapy will remain 
as  one  of  the  main  forms  of  treatment  for  thyroid 
disorders for the foreseeable future. Clearly this form of 
therapy  stands  as  a  benchmark  against  which  all  new 
forms of radionuclide therapy can be judged. 
 
Radionuclide Synovectomy 
Radionuclide synovectomy is widely used in many 
centres  throughout  the  world.  Direct  injection  of 
radioactivity into the joint spaces is used for the purpose 
of synovectomy. The radionuclide of choice is dictated 
by the size of the joint space. Approximately 185 MBq 
90Y-colloid is used for the treatment of knee joints, where 
it is estimated that the order of 100 Gy is delivered to the 
synovium.  74-150  MBq 
186Re-sulphide  is  used  to  treat 
the  hip,  shoulder  and  ankles  and  small 
metatarsophalangeal/metacarpophalangeal joints may be 
treated  with  10-40  MBq 
169Er-citrate  colloid.  In 
comparison  with  surgical  synovectomy,  radionuclide 
synovectomy  produces  comparable  results,  is  less 
expensive and allows the patient to remain ambulatory. It 
is often considered the initial procedure of choice for the 
treatment of patients with hemarthrosis in hemophilia. In 
addition,  local  instillation  of  radiopharmaceuticals  can 
effectively  reduce  effusions  after  implantation  of 
prosthesis [10]. 
 
Polycythaemia 
Treatment  regimens  for  polycythaemia  are  usually 
based  on  an  intravenous  injection  of  74-111  MBq 
32P 
orthophosphate  (PO4
3-)  per  square  meter  body  surface 
area. 
32P is incorporated into the nucleic acids of rapidly 
proliferating  cells.  The  therapeutic  aim  is  to  suppress 
hyperproliferative cells rather than to eradicate them. The 
clinical use of 
32P therapy in polycythaemia is variable 
and  the  widespread future of  this  form  of  treatment  is 
uncertain. 
 
 
CURRENT  AND  EVOLVING  RADIOPHARMACEUTICAL 
THERAPIES 
 
MIBG 
Metaiobenzylguanidine (MIBG) is a catecholamine 
analogue similar to noradrenalin, which accounts for the 
uptake  of  this  radiopharmaceutical  in  catecholamine 
storage  vesicles.  It  is  used  for  diagnostic  imaging 
radiolabelled  in  the  form  of 
123I-MIBG  (Figure  1), 
however when radiolabelled with 
131I it is used for the 
treatment  of  neuroectodermal  tumours  such  as 
neuroblastoma  (which  is  the  second  commonest  solid 
tumour in children), phaeochromocytoma and carcinoid. 
The success of this therapeutic agent has resulted in its 
use as a first line treatment in metastatic neuroblastoma. 
Other approaches include the combination of 
131I-MIBG 
with  chemotherapy  and  blood  stem  cell  support.  The 
majority of neuroendocrine tumours also possess a high 
density of somatostatin receptors offering an alternative 
approach  with  somatostatin  receptor  radiopharma-
ceuticals [11]. A.C. Perkins. Biomed Imaging Interv J 2005; 1(2):e9  4 
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Radiopeptide conjugates 
Interest  in  synthetic  peptides  has  been  growing 
steadily  over  the  past  10  years  and  a  number  of 
radiolabelled  agents  have  a  most  promising  future  as 
agents  for  targeted  radionuclide  therapy  [12].  Low 
molecular  weight  peptides  (3,500  Daltons;  usually  less 
than  30-40  amino  acids  in  length)  have  the  desirable 
properties of fast clearance, rapid tissue penetration, and 
low antigenicity. These molecules can be produced easily 
and  inexpensively  and  therefore  offer  an  attractive 
vehicle  for  clinical  use  and  commercial  production. 
Examples  of  current  radiopharmaceuticals  include 
peptide  hormones  such  as  somatostatin,  vasoactive 
intestinal  peptide,  melanocyte  stimulating  hormone, 
oestrogens and progesterone. Of these, somatostatin has 
proven to be of the greatest interest. Somatostatin is a 
peptide  hormone  consisting  of  14  amino  acids  and  is 
naturally  present  in  the  hypothalamus,  brain  stem, 
gastrointestinal  tract  and  pancreas.  The 
99mTc-labelled 
somatostatin analogue, depreotide is a promising tracer 
for  discriminating  between  malignant  and  benign  lung 
lesions [13]. An example of the highly positive uptake 
that can be visualised in patients with small cell cancer of 
the lung is given in Figure 2. Clearly a tracer having such 
high uptake would offer potential for targeted therapy, 
however the high uptake in the liver and kidneys remain 
limiting factors. 
 
 
 
Figure  1  Anterior  (left)  and  posterior  (right)  whole  body  scan  of  a 
patient with phaeochromocytoma of the right adrenal seen as a small 
intense  focus  of  uptake.  These  diagnostic  images  acquired  22  hours 
after administration of 
123I-MIBG can be used to assess the prospects 
for therapy with 
131I-MIBG. Uptake of tracer can also be seen in the 
salivary glands, liver and urinary tract. 
 
 
A derivative of somatostatin labelled with 
111In has 
been  widely  used  as  an  imaging  agent  (Ocreoscan
TM). 
Clinical  trials  have  been  undertaken  with  therapeutic 
amounts  of  this  radiopharmaceutical,  however 
111In  is 
poorly suited for therapy and current studies using 
90Y 
are proving to be more promising [14]. In further trials 
the results obtained with 
90Y-DOTA(0)-Tyr(3)-octreotide 
and 
177Lu-DOTA(0)-Tyr(3)-octreotate  are  very 
encouraging  in  terms  of  tumour  regression  [15,16]. 
Radiolabelled peptides remain as one of the most highly 
promising vectors for targeted radionuclide therapy. 
 
Bone seeking agents 
The  growth  of  bone  metastases  involves  multiple 
processes including tumour-cell proliferation, cell-matrix 
detachment,  cell  migration,  angiogenesis  and 
intravasation.  The  exquisite  uptake  of  bone  seeking 
agents is evident from the 
99mTc-phosphonate bone scan 
which  is  one  of  the  most  common  diagnostic  nuclear 
medicine  procedures  carried  out  worldwide. 
Radionuclide  bone  scintigraphy  with 
99mTc  is  highly 
sensitive but has variable specificity. The process relies 
on  the  detection  of  an  osteoblastic  reaction  in  the 
presence  of  bone  damage.  The  sensitivity  of 
99mTc 
scintigraphy  for  detecting  bone  metastases  has  been 
reported to range from 62% to 98%, but false positive 
rates as high as 40% have been reported [17,18]. Bone 
scintigraphy  is  more  sensitive  and  more  specific  than 
plain x-ray films and computed tomography (CT), while 
magnetic  resonance  imaging  (MRI)  is  considered  by 
some to be superior to bone scan in evaluating vertebral 
metastases.  
 
 
 
Figure  2  Anterior  image  of  the  thorax  of  a  patient  demonstrating 
intense uptake of the 99mTc-labelled somatostatin analog Depreotide 
(Neospect
TM) in a solitary large mass in the left lung. High liver and 
renal uptake can also be seen. 
 
 
The high uptake of bone seeking agents has led to 
the  widespread  use  of  beta  emitting  agents  for  the 
palliation of painful bone metastases from carcinoma of 
the  prostate  and  breast  [19,20].  The  main 
radiopharmaceuticals  available  include 
153Sm-EDTMP, 
89Sr-chloride, 
153Sm-EDTMP, 
186Re-HEDP  and A.C. Perkins. Biomed Imaging Interv J 2005; 1(2):e9  5 
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117mSn(IV)-DTPA. 
89Sr  and 
153Sm  radiopharmaceuticals 
are  the  most  widely  approved  radionuclides  for  the 
palliation of pain from metastatic bone cancer throughout 
U.S., Europe and Asia. Radiopharmaceutical treatments 
generally provide effective pain relief with response rates 
of between 40% and 95%. Pain relief starts at between 
one  to  four weeks  after  the  initiation of  treatment  and 
continues for up to 18 months and reduces analgesic use 
in many patients. Mild and reversible thrombocytopenia 
and  neutropenia  are  the  most  common  toxic  effects. 
Continued pain relief may be achieved in many patients 
by  repeat  administration.  The  effectiveness  of 
radiopharmaceutical  therapy  can  be  increased  when 
combined with chemotherapeutic agents. 
A particularly promising conjugate for the future is 
based on the 
188Re produced from the tungsten generator 
system. 
188Re is in the same periodic group as 
99mTc and 
the  tungsten  generator  has  many  similarities  to  the 
molybdenum generator, with the potential of becoming 
its  therapeutic  equivalent  for  the  production  of  a  wide 
range  of  therapeutic  radiopharmaceutical  conjugates. 
Liepe et al. [21] have demonstrated 
188Re-HEDP to be an 
effective  radiopharmaceutical  used  in  the  palliative 
treatment of metastatic bone pain in prostate cancer with 
minimal bone marrow toxicity. In this study 76% of the 
patients  treated  described  relief  of  bone  pain  without 
increase of analgesic intake.  
In  the  future  radiopharmaceutical  treatments  may 
become  of  important  clinical  value  for  the  therapy  of 
bone metastases rather than palliation. Some studies with 
89Sr and 
153Sm have indicated a reduction of hot spots on 
bone scans in up to 70% of patients suggesting a possible 
tumouricidal action. Further clinical trials are needed to 
determine  the  optimum  combination  of  radionuclide 
conjugate and dose schedule for effective therapy. 
 
Radioimmunotherapy 
The  concept  of  using  antibodies  to  deliver 
substances to tumour cells was first suggested by Paul 
Ehrlich in 1896 when he coined the term “magic bullets”. 
A  ‘vehicle’  with  specificity  for  a  receptor  expressed 
solely on malignant cells serves as a carrier molecule for 
a cytotoxic agent. Delivery of the radionuclide to tumour 
cells  causes  specific  cell  killing  while  sparing  normal 
cells  the  cytotoxic  effects.  The  specificity  of  the 
antibody-antigen  interaction  is  indisputable  therefore 
antibodies  are  powerful  targeting  molecules.  The 
development of monoclonal antibody technology in 1975 
by  the  two  research  scientists  Kohler  and  Milstein  in 
England has led to the production of large amounts of 
antibody  of  reproducible  and  precise  specificity.  This 
resulted in a dramatic increase in interest in the field of 
antibody-targeted therapeutics. In the early 1980s, there 
was a general belief that Ehrlich’s theory was close to 
being realised with early publications showing excellent 
sensitivity  and  specificity  for  the  in  vivo  detection 
(immunoscintigraphy) of colon and ovarian cancer and 
melanoma  [22-25].  This  raised  the  possibility  that 
antibodies could be used, not only to detect cancer but 
also to treat it. Over the past 20 years there has been a 
great  deal  of  work  on  the  construction  of  antibody 
conjugates  of  different  molecular  designs  [26]  and 
incorporating  different  radiolabels  [4].  Much  progress 
has been made and licensed therapeutic products are now 
emerging for clinical use. 
In  order  for  radioimmunotherapy  to  be  successful 
the tumour must be accessible to the immunoconjugate 
through the chosen route of administration. Intravenous 
injection  is  the  most  common  form  of  administration. 
However  systemic  administration  of  an  immuno-
conjugate can result in sensitisation of the host immune 
system, particularly if the antibody is of murine origin. 
This  can  result  in  the  formation  of  human  anti  mouse 
antibody (HAMA) that can cause increased clearance of 
subsequent  treatments  and  may  even  cause  serious 
anaphylactic  reactions  in  the  patient.  Another  problem 
with systemic administration is the potential toxicity to 
organs such as the kidneys and liver that would normally 
clear  such  macromolecules  from  the  circulation.  One 
approach  that  limits  the  problems  posed  by  HAMA 
response and hepatic and renal toxicity is to administer 
the immunoconjugate locally to the site of the tumour. 
This can be achieved in some cases by injection directly 
in to the tumour mass. This approach has been taken for 
the treatment of some brain tumours such as glioma [27]. 
In addition, some tumours such as those in the bladder, 
grow  in  body  cavities  that  shield  them  from  the  host 
immune  system.  Intravesical  antibody  targeted  therapy 
provides advantages over systemic administration in that 
no HAMA response is generated and higher doses of the 
therapeutic agent can be given without causing problems 
of non-target organ toxicity. Phase I studies have been 
undertaken  with 
67Cu-labelled  anti  mucin  antibody  for 
the  treatment  of  superficial  bladder  tumours  [28]. 
However 
67Cu is not widely available and one interesting 
possibility is the use of 
188Re-labelled antibody for this 
application [29]. An example of the intravesical targeting 
of antibody to bladder tumour from the author’s work is 
shown  in  Figure  3.  It  is  obvious  however  that  only  a 
limited  number  of  tumour  types  fulfil  the  criterion  for 
intravesical therapy and this route of administration will 
not allow efficient targeting of distant micrometastases. 
The  first  therapeutic  antibody  products  to  attract 
commercial  interest  were  for  the  treatment  of  diffuse 
haematological  malignancies  [30].  In  1997  the  first 
antibody  conjugate  to  be  approved  by  the  FDA  for 
targeted  cancer  therapy,  was  an  anti-CD20  antibody 
(rituximab)  for  the  treatment  of  Non-Hodgkin’s 
Lymphoma  (NHL).  NHL  is  inherently  sensitive  to 
radiation  and  is  one  of  a  number  of  haematological 
malignancies that can benefit from radioimmunotherapy 
[31]. Radiotherapy can be curative in early stage NHL 
but is less easily applied to advanced stage disease. One 
attractive feature of radiopharmaceutical therapy is that 
there appears to be a synergistic activity between naked 
antibody  and  the  radionuclide.  Prospective  trials 
comparing 
90Y-ibritumomab  tiuxetan  with  single-agent 
rituximab are showing an overall response rate (ORR) to 
90Y-ibritumomab  tiuxetan  of  80%  with  34%  complete 
response.  Similar  results  have  been  reported  with 
90Y-
ibritumomab  tiuxetan  in  patients  with  relapsed  or 
refractory low-grade NHL with mild thrombocytopenia. A.C. Perkins. Biomed Imaging Interv J 2005; 1(2):e9  6 
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Safety  data  from  patients  entered  into  studies  have 
demonstrated side effects that are mainly hematological 
and transient [32,33]. Initially two licensed products were 
commercially  available,  Zevalin
TM  (ibritumomab 
tiuxetan) and Bexxar
TM. Both antibodies react with the 
CD20 antigen, which is important for cell cycle initiation 
expressed only on B-lineage cells and is considered to 
trigger  apoptosis.  Bexxar
TM  is  radiolabelled  with 
131I 
whereas  Zevalin
TM  has 
90Y  as  the  therapeutic 
radionuclide. Clearly, this will affect the clinical utility of 
the product since Bexxar
TM may be used for imaging to 
assess  treatment  planning,  uptake  and  dosimetry, 
wheareas  Zevalin
TM  is  suitable  for  outpatient 
administration.  It  will  be  interesting  to  see  how 
widespread  these  therapeutic  radiopharmaceuticals  are 
used in future. 
 
 
(a) 
 
 
(b) 
 
Figure 3 (a) Intravenous urogram showing large superficial transitional 
cell tumour in the left side of the bladder; (b) anterior gamma camera 
image showing uptake of 
188Re-C595 anti-mucin antibody, following 
intravesical administration for 1 hour. 
FUTURE PROSPECTS 
 
The  fundamental  concept  of  external  beam 
radiotherapy is the delivery of a cancerocidal dose of 60-
70 Gy to tumour tissue without critical damage to healthy 
organs. In practice the treatment of disseminated cancers 
is limited to 30-40 Gy in order to spare normal tissue 
damage. It is with this promise of minimising irradiation 
of normal tissues that radionuclide therapy stands to gain 
future  prominence.  Recent  studies  using  functional 
metabolic  tracers  such  as  FDG  are  beginning  to  show 
fundamental  errors  in  the  definition  of  tumour  volume 
based on  purely  anatomical  imaging  such  as  x-ray  CT 
[34].  In  the  same  way  that  FDG  can  demonstrate 
functioning tumour tissue, the targeting of a more potent 
radionuclide  to  molecular  functioning  tumour  tissue 
should  offer  an  advantage  in  the  treatment  of  a  wide 
spectrum  of  pathologies.  Whereas  therapeutic 
radiopharmaceuticals based on 
131I-sodium iodide for the 
treatment  of  thyroid  disease  and 
131I-MIBG  for  neural 
crest tumours are well established with an assured role in 
the  foreseeable  future,  the  use  of  radionuclides  for 
polycythaemia and synovectomy are less certain.  
Radiopharmaceutical  treatments  of  the  future  will 
certainly employ antibodies, peptides and labelled drug 
molecules, however there are still some new technologies 
to be developed for use in nuclear oncology. Dramatic 
growth  in  the  biotechnology  sector  has  led  to  new 
techniques  for  the  design,  selection  and  production  of 
ligands capable of specific molecular recognition. These 
alternative molecular entities can be generated rapidly to 
recognise  molecular  targets  such  as  tumour-associated 
antigens. One promising approach is the production of 
receptor binding molecules based on specific nucleic acid 
sequences that are capable of recognising a wide array of 
target molecules. These oligonuclide ligands are known 
as aptamers [35,36]. The term aptamer is derived form 
the Latin word “aptus” meaning “to fit”. The technology 
that allows production of aptamer molecules is known as 
systematic  evolution  of  ligands  by  exponential 
enrichment (SELEX). These molecules offer the prospect 
of good tumour penetration, rapid uptake and clearance, 
thus  providing  effective  vehicles  for  cytotoxic  agents. 
Manipulation of the molecular weight of these constructs 
utilising  methodologies  to  produce  polymeric  aptamer 
complexes should achieve an optimum balance between 
rapid renal clearance that leads to premature elimination 
of  the  complex  from  the  system  and  adequate  tumour 
uptake for diagnostic imaging and targeted therapy. 
The choice of the optimum radionuclide is still to be 
determined although 
90Y appears to be emerging as an 
important therapeutic label. In future, it is highly likely 
that 
188Re from the tungsten/rhenium generator will play 
an important role, particularly as this provides a reliable 
source  of  a  therapeutic  radionuclide  over  a  sustained 
period of up to 6 months from one generator, this being 
of  particular  value  to  remote  and  developing  countries 
wishing to benefit from these procedures.  
Another  exciting  area  of  interest  is  the  use  of 
conjugates based on alpha emitters such as 
211At, 
212Bi 
and 
212Tb [37]. These radionuclides have energies of an 
order  of  magnitude  greater  than  beta  emitters  having A.C. Perkins. Biomed Imaging Interv J 2005; 1(2):e9  7 
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linear  energy  transfer  of  about  100  times  greater  than 
beta particles giving them a range of 50-90 mm in tissue. 
Typically absorption of alpha particles can result in 0.25 
Gy in 10 mm cell diameter. In vitro studies show that 
alpha therapy is more cytotoxic by one to two orders of 
magnitude  to  targeted  cells  than  non-specific  alpha 
conjugates,  specific  beta  emitting  conjugates  or  free 
radionuclides [38]. Currently these forms of therapy are 
entering Phase I and II trials for treatment of melanoma, 
leukaemia and tumours of breast, pancreas, and prostate. 
Initial results from clinical trials of 
223Ra given as radium 
chloride at doses of up to 350 kBq/kg for palliation of 
metastatic  bone  pain  from  prostate  carcinoma  are  also 
showing potential value [39]. 
In  conclusion  it  is  evident  that  the  future  of 
molecular  targeted  radionuclide  therapy  is  assured  and 
this modality will prove to be a valuable therapeutic tool 
of  particular  benefit  in  clinical  oncology.  Although  at 
present  largely  based  on 
131I  and 
90Y,  the  choice  of 
therapeutic radionuclide is widening to include generator 
products and possibly alpha emitters. Treatment regimes 
will be developed to employ dose fractionation to allow 
outpatient  administration.  However,  the  routine 
application of therapeutic radiopharmaceuticals is likely 
to  be  limited  to  specialised  centres  with  the  expertise, 
facilities and authorisation for handling large amounts of 
radioactivity. 
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